GMED 📈 Globus Medical - Overview

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US3795772082

GMED: Spine, Orthopedic, Trauma, Joint, Biologic, Surgical Implants

Globus Medical is a medical device company that develops and commercializes a wide range of healthcare solutions, primarily focusing on musculoskeletal disorders. Their product portfolio includes an array of spine products, such as traditional fusion implants, which encompass pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices. These solutions are designed to treat various conditions, including degenerative and congenital disorders, deformity, tumors, and trauma injuries. The company also offers motion preservation technologies, including dynamic stabilization, total disc replacement, and interspinous distraction devices, providing patients with alternative treatment options.

In addition to their spine products, Globus Medical offers interventional solutions for treating vertebral compression fractures, as well as regenerative biologic products, comprising allografts and synthetic alternatives. Their product line also extends to orthopedic trauma treatment, featuring fracture plates, compression screws, intramedullary nails, and external fixation systems. Furthermore, the company provides hip and knee joint solutions, including modular hip stems, acetabular cups, and a range of knee arthroplasty implants, such as posterior stabilizing and cruciate retaining implants. This comprehensive portfolio enables Globus Medical to cater to a broad spectrum of musculoskeletal needs, making them a significant player in the healthcare industry.

Globus Medical's distribution network is multifaceted, with the company selling its products through direct sales representatives, distributors, and independent sales agents, particularly for hip and knee products. This strategic approach allows them to maintain a strong presence in the market, both domestically and internationally. With its headquarters in Audubon, Pennsylvania, and a strong online presence, Globus Medical continues to expand its reach, providing innovative healthcare solutions to patients worldwide. The company's commitment to research and development, coupled with its extensive product range, positions them as a leading medical device company, dedicated to improving patient outcomes and advancing the field of musculoskeletal healthcare.

Additional Sources for GMED Stock

GMED Stock Overview

Market Cap in USD 11,657m
Sector Healthcare
Industry Medical Devices
GiC Sub-Industry Health Care Equipment
IPO / Inception 2012-08-03

GMED Stock Ratings

Growth 5y 32.6%
Fundamental 15.0%
Dividend -
Rel. Strength Industry 1053
Analysts 3.87/5
Fair Price Momentum 83.27 USD
Fair Price DCF 66.82 USD

GMED Dividends

No Dividends Paid

GMED Growth Ratios

Growth Correlation 3m 85.2%
Growth Correlation 12m 88.7%
Growth Correlation 5y 17.9%
CAGR 5y 6.90%
CAGR/Mean DD 5y 0.36
Sharpe Ratio 12m 1.36
Alpha 28.05
Beta 1.00
Volatility 30.32%
Current Volume 2828.7k
Average Volume 20d 928.3k
What is the price of GMED stocks?
As of December 21, 2024, the stock is trading at USD 82.63 with a total of 2,828,721 shares traded.
Over the past week, the price has changed by +0.25%, over one month by -1.15%, over three months by +16.97% and over the past year by +59.30%.
Is Globus Medical a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Globus Medical is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 15.01 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of GMED as of December 2024 is 83.27. This means that GMED is currently overvalued and has a potential downside of 0.77%.
Is GMED a buy, sell or hold?
Globus Medical has received a consensus analysts rating of 3.87. Therefor, it is recommend to buy GMED.
  • Strong Buy: 5
  • Buy: 4
  • Hold: 5
  • Sell: 1
  • Strong Sell: 0
What are the forecast for GMED stock price target?
According to ValueRays Forecast Model, GMED Globus Medical will be worth about 92.1 in December 2025. The stock is currently trading at 82.63. This means that the stock has a potential upside of +11.51%.
Issuer Forecast Upside
Wallstreet Target Price 90.5 9.6%
Analysts Target Price 67.3 -18.6%
ValueRay Target Price 92.1 11.5%